简单规则、O-RADS、ADNEX及SRR模型:单肿瘤中心对诊断预测模型单独及联合(两步策略)评估附件肿块及卵巢肿瘤恶性风险的验证
本研究在单肿瘤中心回顾性纳入2018年1月至2021年12月连续就诊的附件肿块患者,比较ADNEX模型、O-RADS、SRR评估及基于简单规则(SR)的两步策略(SR+SRR、SR+ADNEX)在术前鉴别良恶性附件肿块中的性能。共514例女性,良性400例(77.8%),恶性114例(22.2%)。在恶性风险>10%阈值下,O-RADS的敏感度最高,与ADNEX模型及SR+ADNEX模型相似;SR+ADNEX模型具有更高的特异度和阳性预测值。
要点
- 共纳入514例附件肿块患者,良性400例(77.8%),恶性114例(22.2%)。
- 恶性风险>10%阈值下,O-RADS敏感度0.93(95%CI 0.87-0.97),特异度0.89(95%CI 0.96-0.92)。
- SR+ADNEX模型特异度0.93(95%CI 0.90-0.96),高于SR+SRR的0.92(95%CI 0.89-0.94)。
核心结论
- O-RADS的敏感度最高,与ADNEX模型及SR+ADNEX模型相似。
- SR+ADNEX模型具有更高的性能准确度,特异度和阳性预测值更高。
- 对SR结果不确定者应用SR+ADNEX模型的两步策略便于临床评估。
研究设计与样本
- 回顾性研究,2018年1月至2021年12月在单肿瘤中心连续纳入附件肿块患者。
- 共纳入514例女性,其中良性卵巢肿瘤400例(77.8%),恶性肿瘤114例(22.2%)。
- 比较ADNEX模型、O-RADS、SRR评估及两步策略(SR+SRR、SR+ADNEX)的性能。
主要发现
- 恶性风险>10%阈值下,ADNEX模型敏感度0.92(95%CI 0.86-0.96),特异度0.88(95%CI 0.85-0.91)。
- O-RADS敏感度0.93(95%CI 0.87-0.97),特异度0.89(95%CI 0.96-0.92)。
- SRR敏感度0.88(95%CI 0.80-0.93),特异度0.84(95%CI 0.80-0.87)。
- 应用SR时,109例(21.2%)结果不确定。
- 两步策略SR+SRR敏感度0.88(95%CI 0.80-0.93),特异度0.92(95%CI 0.89-0.94);SR+ADNEX模型敏感度0.90(95%CI 0.83-0.95),特异度0.93(95%CI 0.90-0.96)。
关键数值与推荐
- ADNEX模型在恶性风险>10%阈值下敏感度0.92(95%CI 0.86-0.96),特异度0.88(95%CI 0.85-0.91)。
- O-RADS在恶性风险>10%阈值下敏感度0.93(95%CI 0.87-0.97),特异度0.89(95%CI 0.96-0.92)。
- SRR在恶性风险>10%阈值下敏感度0.88(95%CI 0.80-0.93),特异度0.84(95%CI 0.80-0.87)。
- SR+SRR两步策略敏感度0.88(95%CI 0.80-0.93),特异度0.92(95%CI 0.89-0.94)。
- SR+ADNEX模型两步策略敏感度0.90(95%CI 0.83-0.95),特异度0.93(95%CI 0.90-0.96)。
临床怎么用
- 作者认为,对SR结果不确定者应用SR+ADNEX模型的两步策略便于临床评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare performance of Assessment of Different NEoplasias in the adneXa (ADNEX model), Ovarian-Adnexal Reporting and Data System (O-RADS), Simple Rules Risk (SRR) assessment and the two-step strategy based on the application of Simple Rules (SR) followed by SRR and SR followed by ADNEX in the pre-operative discrimination between benign and malignant adnexal masses (AMs). METHODS: We conducted a retrospective study from January-2018 to December-2021 in which consecutive patients with at AMs were recruited. Accuracy metrics included sensitivity (SE) and specificity (SP) with their 95% confidence intervals (CI) were calculated for ADNEX, O-RADS and SRR. When SR was inconclusive a "two-step strategy" was adopted applying SR + ADNEX model and SR + SRR assessment. RESULTS: A total of 514 women were included, 400 (77.8%) had a benign ovarian tumor and 114 (22.2%) had a malignant tumor. At a threshold malignancy risk of >10%, the SE and SP of ADNEX model, O-RADS and SRR were: 0.92 (95% CI, 0.86-0.96) and 0.88 (95% CI, 0.85-0.91); 0.93 (95% CI, 0.87-0.97) and 0.89 (95% CI, 0.96-0.92); 0.88 (95% CI, 0.80-0.93) and 0.84 (95% CI, 0.80-0.87), respectively. When we applied SR, 109 (21.2%) cases resulted inconclusive. The SE and SP of two-step strategy SR + SRR assessment and SR + ADNEX model were 0.88 (95% CI, 0.80-0.93) and 0.92 (95% CI, 0.89-0.94), SR + ADNEX model 0.90 (95% CI, 0.83-0.95) and 0.93 (95% CI, 0.90-0.96), respectively. CONCLUSIONS: O-RADS presented the highest SE, similar to ADNEX model and SR + ADNEX model. However, the SR + ADNEX model presented the higher performance accuracy with the higher SP and PPV. This two-step strategy, SR and ADNEX model applicated to inconclusive SR, is convenient for clinical evaluation.
引用
- Spagnol G, Marchetti M, De Tommasi O, et al. Simple rules, O-RADS, ADNEX and SRR model: Single oncologic center validation of diagnostic predictive models alone and combined (two-step strategy) to estimate the risk of malignancy in adnexal masses and ovarian tumors. Gynecol Oncol. 2023. PMID: 37660412. doi:10.1016/j.ygyno.2023.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。